Form 4: Adial Pharmaceuticals Director James Newman Jr. Granted 28,000 Stock Options

Adial Pharmaceuticals, Inc. director James W. Newman, Jr. was granted 28,000 stock options with an exercise price of $0.688, vesting over 36 months.

Summary

• James W. Newman, Jr., a Director of Adial Pharmaceuticals, Inc. (ADIL), reported the acquisition of 28,000 derivative securities in the form of stock options.
• The transaction date for this grant was May 29, 2025.
• Each stock option has an exercise price of $0.688.
• The options will vest pro rata on a monthly basis over a period of 36 months, commencing from May 29, 2025.
• The expiration date for these stock options is May 28, 2035.
• Following this reported transaction, James W. Newman, Jr. directly beneficially owns 28,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a Form 4 primarily reports a transaction, the grant of options to a director is a positive signal of alignment between management and shareholder interests, without indicating any immediate negative operational or financial news.

Positives

• The grant of stock options to a director, James W. Newman, Jr., aligns his interests with those of the company's shareholders, as the value of the options is tied to the future performance of ADIL's common stock.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization for long-term value creation.

Future Outlook

The stock options granted to James W. Newman, Jr. will vest pro rata on a monthly basis over the next 36 months, commencing May 29, 2025, indicating a future incentive structure tied to the company's performance over this period.

Industry Context

The granting of stock options to directors is a common practice across various industries, including pharmaceuticals, to incentivize long-term commitment and align management interests with shareholder value. This filing reflects a routine compensation event within the industry.

Comparison to Industry Standards

• The practice of granting stock options as part of director compensation is a widely accepted standard across publicly traded companies, including those in the biotechnology and pharmaceutical sectors.
• The vesting schedule of 36 months is a typical duration for equity grants designed to retain and incentivize directors over a multi-year period, comparable to practices seen in companies like Pfizer or Moderna for their non-executive directors, though specific grant sizes and exercise prices vary based on company size, performance, and individual roles.

Related Party Transactions

• The acquisition of stock options by James W. Newman, Jr., a director of Adial Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align the director's financial interests with those of the shareholders, potentially encouraging decisions that enhance long-term stock value.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The stock options will continue to vest monthly over the next 36 months, subject to the terms of the grant.

Key Dates

Keywords

Adial Pharmaceuticals, ADIL, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Beneficial Ownership, James W. Newman Jr.